The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened.
News|Articles|May 27, 2026
The Current State of DEI in Clinical Trials: Progress, Pressure, and the Path Forward
Author(s)Andy Studna, Senior Editor
Despite political headwinds, life sciences leaders are holding their ground on DEI, but translating organizational commitment into representative enrollment requires structural changes to protocol design, site selection, and community engagement that most of the industry has yet to fully make.
Advertisement
Advertisement
The industry has been discussing clinical trial diversity, equity, and inclusion (DEI) for decades. What is different now is the convergence of regulatory expectations, organizational accountability structures, and a political environment that is simultaneously creating pressure and hesitancy. Understanding where progress is real, where it is stalling, and what is actually working is more important than ever.
Related to this article
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Mixed FSP and FSO models are gaining ground as sponsors seek agility and resource flexibility, but the oversight infrastructure, audit trails, and accountability structures needed to run them well and survive regulatory inspection are consistently lagging behind the model itself.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
Advertisement
Advertisement